Sonnet BioTherapeutics to Present at LIVE! with Webull Corporate Connect: Healthcare Investment Webinar
Sonnet BioTherapeutics (NASDAQ: SONN), a clinical-stage company focused on developing targeted immunotherapeutic drugs, has announced its participation in an upcoming healthcare investment webinar. Dr. Pankaj Mohan, the company's CEO, will present at the LIVE! with Webull Corporate Connect: Healthcare Investment Webinar on Wednesday, January 29th, 2025 at 2:40 PM ET.
The virtual biotech investment event provides an opportunity for investors to learn more about Sonnet's developments in the immunotherapeutics space. Interested participants can access the presentation through the provided registration link.
Sonnet BioTherapeutics (NASDAQ: SONN), un'azienda in fase clinica focalizzata nello sviluppo di farmaci immunoterapici mirati, ha annunciato la sua partecipazione a un prossimo webinar di investimento nel settore sanitario. Dr. Pankaj Mohan, CEO dell'azienda, presenterà al LIVE! with Webull Corporate Connect: Healthcare Investment Webinar mercoledì 29 gennaio 2025 alle 14:40 ET.
L'evento virtuale di investimento biotech offre un'opportunità agli investitori per saperne di più sui progressi di Sonnet nel campo degli immunoterapici. I partecipanti interessati possono accedere alla presentazione tramite il link di registrazione fornito.
Sonnet BioTherapeutics (NASDAQ: SONN), una empresa en etapa clínica centrada en el desarrollo de medicamentos inmunoterapéuticos dirigidos, ha anunciado su participación en un próximo seminario web de inversión en salud. Dr. Pankaj Mohan, CEO de la empresa, presentará en el LIVE! with Webull Corporate Connect: Healthcare Investment Webinar el miércoles 29 de enero de 2025 a las 2:40 PM ET.
El evento virtual de inversión en biotecnología brinda una oportunidad a los inversores para conocer más sobre los desarrollos de Sonnet en el campo de los inmunoterapéuticos. Los participantes interesados pueden acceder a la presentación a través del enlace de registro proporcionado.
Sonnet BioTherapeutics (NASDAQ: SONN), 목표 면역 치료제를 개발하는 임상 단계의 회사가 다가오는 의료 투자 웨비나에 참여한다고 발표했습니다. Dr. Pankaj Mohan, 회사의 CEO가 LIVE! with Webull Corporate Connect: Healthcare Investment Webinar에서 2025년 1월 29일 수요일 오후 2시 40분 ET에 발표할 것입니다.
가상 생명공학 투자 이벤트는 투자자들에게 Sonnet의 면역 치료제 분야의 발전에 대해 더 알아볼 수 있는 기회를 제공합니다. 관심 있는 참가자들은 제공된 등록 링크를 통해 발표에 접근할 수 있습니다.
Sonnet BioTherapeutics (NASDAQ: SONN), une entreprise en phase clinique axée sur le développement de médicaments immunothérapeutiques ciblés, a annoncé sa participation à un prochain webinaire d'investissement en santé. Dr. Pankaj Mohan, le PDG de l'entreprise, interviendra lors de LIVE! with Webull Corporate Connect: Healthcare Investment Webinar le mercredi 29 janvier 2025 à 14h40 ET.
L'événement virtuel d'investissement en biotechnologie offre aux investisseurs l'occasion d'en savoir plus sur les développements de Sonnet dans le domaine des immunothérapeutiques. Les participants intéressés peuvent accéder à la présentation via le lien d'inscription fourni.
Sonnet BioTherapeutics (NASDAQ: SONN), ein klinisches Unternehmen, das sich auf die Entwicklung gezielter immuntherapeutischer Medikamente konzentriert, hat seine Teilnahme an einem bevorstehenden Webinar über Gesundheitsinvestitionen angekündigt. Dr. Pankaj Mohan, der CEO des Unternehmens, wird am Mittwoch, den 29. Januar 2025, um 14:40 Uhr ET beim LIVE! with Webull Corporate Connect: Healthcare Investment Webinar präsentieren.
Die virtuelle Biotech-Investitionsveranstaltung bietet Investoren die Möglichkeit, mehr über die Entwicklungen von Sonnet im Bereich der Immuntherapeutika zu erfahren. Interessierte Teilnehmer können über den bereitgestellten Registrierungslink auf die Präsentation zugreifen.
- None.
- None.
Live webcast on Wednesday, January 29th at 2:40 PM ET
PRINCETON, NJ, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (the “Company” or “Sonnet”) (NASDAQ: SONN), a clinical-stage company developing targeted immunotherapeutic drugs, today announced that Pankaj Mohan, Ph.D., Chief Executive Officer of Sonnet will present at LIVE! with Webull Corporate Connect: Healthcare Investment Webinar being held on January 29, 2025.
Conference Details:
Conference: LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar
Date/Time: Wednesday, January 29, 2025 at 2:40 PM ET
Presenter: Pankaj Mohan, Ph.D., Chief Executive Officer
Registration Link: HERE
About Webull Financial
Webull Financial is a leading online brokerage platform committed to empowering self-directed investors with innovative tools and cutting-edge technology. With low-cost trading on a wide range of assets, advanced charting tools, and real-time market data, Webull is revolutionizing the way individuals approach investing. The user-centric approach and commitment to staying at the forefront of industry trends underscore the mission to provide a seamless and rewarding experience for traders of all levels. Through the Webull Group, Webull Financial and its affiliates combine to serve tens of millions of users from over 180 countries worldwide. Securities and futures trading is offered to customers by Webull Financial LLC (“Webull Financial”), a broker-dealer registered with the Securities and Exchange Commission (SEC) and a futures commission merchant registered with the Commodity Futures Trading Commission (CFTC). Webull Financial is a member of the Financial Industry Authority (FINRA), the National Futures Association (NFA), and the Securities Investor Protection Corporation (SIPC). All investing is subject to risk, including the possible loss of principal. For more information about Webull, visit www.webull.com.
About Sonnet BioTherapeutics Holdings, Inc.
Sonnet is an oncology-focused biotechnology company with a proprietary platform for developing targeted biologic drugs with single or bifunctional action. Known as FHAB (Fully Human Albumin-Binding), the technology utilizes a fully human single chain antibody fragment (scFv) that binds to and "hitch-hikes" on human serum albumin (HSA) for transport to target tissues. Sonnet's FHAB was designed to specifically target tumor and lymphatic tissue, with an improved therapeutic window for optimizing the safety and efficacy of immune modulating biologic drugs. FHAB platform is the foundation of a modular, plug-and-play construct for potentiating a range of large molecule therapeutic classes, including cytokines, peptides, antibodies and vaccines.
Sonnet’s lead program, SON-1010, or IL-12-FHAB, is in development for the treatment of solid tumors and ovarian cancer. SON-1010 is being evaluated in an ongoing Phase 1/2a study through a Master Clinical Trial and Supply Agreement, along with ancillary Quality and Safety Agreements, with Roche in combination with atezolizumab (Tecentriq®) for the treatment of platinum-resistant ovarian cancer (PROC). The Company is also evaluating its second program, SON-1210, an IL12-FHAB-IL15 for solid tumors, in collaboration with the Sarcoma Oncology Center to commence an investigator-initiated and funded Phase 1/2a study for the treatment of pancreatic cancer.
The Company’s SON-080 program is a low dose of rhIL-6 in development for Chemotherapy-Induced Peripheral Neuropathy (CIPN) and Diabetic Peripheral Neuropathy (DPN). SON-080 demonstrated encouraging results in a Phase 1b/2a clinical trial, being well tolerated with no evidence of a pro-inflammatory cytokine response. In October 2024, Sonnet announced an India license agreement with Alkem Laboratories, Inc. who will assume responsibility for advancing development of the SON-080 program into a Phase 2 study in DPN.
Investor Relations Contact:
JTC Team, LLC
Jenene Thomas
908.824.0775
SONN@jtcir.com
FAQ
When is Sonnet BioTherapeutics (SONN) presenting at the Webull Healthcare Investment Webinar?
What will be discussed at the Sonnet BioTherapeutics (SONN) Webull presentation?
Who is presenting for Sonnet BioTherapeutics (SONN) at the Webull Healthcare Investment Webinar?
How can investors attend the Sonnet BioTherapeutics (SONN) Webull presentation?
